Cellectar Biosciences (CLRB) Depreciation & Amortization (CF) (2010 - 2025)

Cellectar Biosciences has reported Depreciation & Amortization (CF) for 16 years, with the latest figure at $49461.0 in Q4 2025.

• Quarterly Depreciation & Amortization (CF) fell 27.87% year-over-year to $49461.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $213597.0 (down 26.76% YoY) and the FY2025 annual result came in at $213597.0, down 26.76% from the prior year.
• Depreciation & Amortization (CF) eased to $49461.0 in Q4 2025 per CLRB's latest filing, from $52277.0 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $88490.0 in Q1 2024 and troughed at $32960.0 in Q3 2022.
• A 5-year average of $49777.0 and a median of $42987.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2024 and 2025: Depreciation & Amortization (CF) surged 107.93% in 2024, then plunged 36.38% in 2025.
• Over 5 years, Depreciation & Amortization (CF) stood at $39291.0 in 2021, then fell by 3.99% to $37724.0 in 2022, then surged by 85.45% to $69960.0 in 2023, then declined by 1.99% to $68571.0 in 2024, then retreated by 27.87% to $49461.0 in 2025.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $49461.0, $52277.0, and $55564.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.